Search results for "Ii Randomized-Trial"

showing 1 items of 1 documents

The SCOPE of definitive chemoradiotherapy in locally advanced esophageal cancer: what direction for the future?

2016

Exclusive chemoradiotherapy (CRT) delivering 50 Gy over 5 weeks with cisplatin and fluorouracil-based chemotherapy is a cornerstone in locally advanced esophageal cancer or non-operable patients since the results of the pivotal study of US Intergroup RTOG-8501 (1). This trial has successfully demonstrated that some patients with esophageal carcinoma may be long-term survivors so that this treatment is now definitely accepted as curative (2). Nevertheless the prognosis is still very disappointing with a 5-year overall survival rate of approximately 25%. Attempts to improve overall survival by escalating the dose of radiotherapy with concurrent cisplatin and fluorouracil has been assessed in …

0301 basic medicinePulmonary and Respiratory MedicineOncologymedicine.medical_specialtymedicine.medical_treatmentLocally advancedCetuximab[SDV.CAN]Life Sciences [q-bio]/CancerOutcomes[SDV.MHEP.PSR]Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tract[ SDV.CAN ] Life Sciences [q-bio]/CancerIntensity-Modulated Radiotherapy03 medical and health sciences0302 clinical medicineInternal medicineCarcinomaMedicineComputingMilieux_MISCELLANEOUSCapecitabineCisplatinChemotherapybusiness.industryCarcinomaInduction ChemotherapyEsophageal cancermedicine.diseaseRadiation-Therapy3. Good healthRadiation therapyEditorial030104 developmental biologyChemoradiationFluorouracil030220 oncology & carcinogenesisIi Randomized-TrialCisplatinbusiness[ SDV.MHEP.PSR ] Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tractChemoradiotherapymedicine.drug
researchProduct